Skip to main content
Premium Trial:

Request an Annual Quote

ISB Partner Accelerator Corrals $22.5M for Bioscience Start-ups

NEW YORK (GenomeWeb News) - Accelerator, a Seattle-based biotech investment and development organization affiliated with the Institute for Systems Biology, has landed over $22.5 million in financing commitments from several sources.
 
Accelerator, which formed in 2003 and has helped to raise a total of $130 million for itself and for start-ups, said it will look to use the funds to "identify, evaluate, finance and manage emerging biotechnology opportunities."
 
Backing for this funding round came from previous investors, including Amgen Ventures, Arch Venture Partners, and OVP Venture Partners. The company said WRF Capital also has committed to chip in financing for Accelerator's projects.
 
ISB will continue to serve as the “key scientific institutional anchor” for Accelerator.
 
"ISB has made significant contributions to Accelerator, with half of the first six investments based upon either ISB-based technologies or opportunities identified for Accelerator by ISB faculty," said the Institute's President, Leroy Hood, in a statement.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.